Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dexlansoprazole MR 30 mg once daily (QD) is approved in adults for the treatment of symptomatic nonerosive gastroesophageal reflux disease (GERD) and maintenance of healed erosive esophagitis (EE); 60 mg is approved for healing EE. The present study assesses the pharmacokinetic (PK) profile and safety of dexlansoprazole MR in adolescent patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Pediatr. Gastroenterol. Nutr.

Title: Journal of pediatric gastroenterology and nutrition

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1536-4801

ISSN (Print): 0277-2116

Publication date (Electronic): Jan 2012

Volume: 54

Issue: 1

Affiliations

[1 ] Takeda Global Research & Development Center, Inc, Deerfield, IL 60015, USA. michael.kukulka@tgrd.com

Article

DOI: 10.1097/MPG.0b013e31822a323a

PubMed ID: 21716130

SO-VID: f5e4b02b-3493-4689-8a1d-642db67a8fca

History

Data availability:

Comments

Comment on this article

scite_

Cited by 7

See all cited by